{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:32Z","timestamp":1784761472513,"version":"3.55.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of omadacycline, a new tetracycline antibiotic. Data Sources: A literature search through PubMed, Google Scholar, and clinicaltrials.gov was conducted (2008 to October 2018) using the search terms omadacycline and PTK-0796. Abstracts presented at recent conferences, prescribing information and information from the FDA and the manufacturer\u2019s website were reviewed. Study Selection and Data Extraction: Preclinical data and published phase 1, 2, and 3 studies were evaluated. Data Synthesis: Omadacycline displays in vitro activity against a wide range of bacteria. Clinical trials have shown that omadacycline is noninferior to linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP). A loading dose of 200 mg intravenously (IV) once or 100 mg IV twice or 450 mg orally for two days is recommended followed by a maintenance dose of 100 mg IV or 300 mg orally once daily. No dosage adjustment is needed in patients with renal or hepatic impairment. Omadacycline is well tolerated, with nausea being a common adverse effect, but is associated with food and drug interactions. Relevance to Patient Care and Clinical Practice: Omadacycline is active against staphylococci, including methicillin-resistant strains, and streptococci, including tetracycline-resistant strains, as well as atypical bacteria. Omadacycline provides clinicians with an additional parenteral and oral option for the treatment of adults with ABSSSI and CABP. Conclusion: Omadacycline is an alternative treatment option for ABSSSI and CABP.<\/jats:p>","DOI":"10.1177\/1060028018818094","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T04:06:13Z","timestamp":1544155573000},"page":"486-500","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Omadacycline: A New Tetracycline Antibiotic"],"prefix":"10.1177","volume":"53","author":[{"given":"John A.","family":"Dougherty","sequence":"first","affiliation":[{"name":"Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allana J.","family":"Sucher","sequence":"additional","affiliation":[{"name":"Regis University, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Shihadeh","sequence":"additional","affiliation":[{"name":"Denver Health Medical Center, Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"bibr1-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"bibr2-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals announces FDA grant of Qualified Infectious Disease Product (QIDP) designation for its lead product candidate, omadacycline. PRNewswire. https:\/\/www.prnewswire.com\/news-releases\/paratek-pharmaceuticals-announces-fda-grant-of-qualified-infectious-disease-product-qidp-designation-for-its-lead-product-candidate-omadacycline-185554432.html. Published January 3, 2013. Accessed October 3, 2018."},{"key":"bibr3-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Paratek announces FDA approval of NUZYRA\u2122 (Omadacycline). Globe Newswire. https:\/\/globenewswire.com\/news-release\/2018\/10\/02\/1600459\/0\/en\/Paratek-Announces-FDA-Approval-of-NUZYRA-Omadacycline.html. Published October 2, 2018. Accessed November 22, 2018."},{"key":"bibr4-1060028018818094","unstructured":"NUZYRA [package insert]. Boston, MA: Paratek Pharmaceu-ticals, Inc; 2018."},{"key":"bibr5-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Omadacycline receives Qualified Infectious Disease Product designation from FDA for an additional indication in uncomplicated urinary tract infections.Globe Newswire. https:\/\/globenewswire.com\/news-release\/2017\/09\/21\/1125813\/0\/en\/Omadacycline-Receives-Qualified-Infectious-Disease-Product-Designation-from-FDA-for-an-Additional-Indication-in-Uncomplicated-Urinary-Tract-Infections.html. Published September 21, 2017. Accessed November 13, 2018."},{"key":"bibr6-1060028018818094","volume-title":"Paper presented at: American Society of Microbiology Meeting","author":"Overcash JS"},{"key":"bibr7-1060028018818094","unstructured":"ClinicalTrials.gov. Oral omadacycline vs oral nitrofurantoin for the treatment of cystitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425396. Published February 7, 2018. Accessed November 13, 2018."},{"key":"bibr8-1060028018818094","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14226.1"},{"key":"bibr9-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"bibr10-1060028018818094","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122120"},{"key":"bibr11-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1177\/2049936117723228"},{"key":"bibr12-1060028018818094","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"bibr13-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2013-0292"},{"key":"bibr14-1060028018818094","unstructured":"ChemSpider Search and Share Chemistry. Minocycline structure. http:\/\/www.chemspider.com\/Chemical-Structure.16735907.html?rid=aafc21d9-ad05-403f-8d31-8aec2de8ce17. Accessed November 13, 2018."},{"key":"bibr15-1060028018818094","unstructured":"ChemSpider Search and Share Chemistry. Omadacycline structure. http:\/\/www.chemspider.com\/Chemical-Structure.20131003.html?rid=4744eadc-7195-464f-9132-590940212a32&page_num=0. Accessed November 13, 2017."},{"key":"bibr16-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"bibr17-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2016.03.011"},{"key":"bibr18-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"bibr19-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"bibr20-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01734-16"},{"key":"bibr21-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18"},{"key":"bibr22-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Omadacycline Paratek Pharmaceuticals Antimicrobial Drugs Advisory Committee(AMDAC) briefing book. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM615849.pdf. Published July 1, 2018. Accessed August 10, 2018."},{"key":"bibr23-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"},{"key":"bibr24-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"bibr25-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02551-17"},{"key":"bibr26-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"bibr27-1060028018818094","unstructured":"US Food and Drug Administration. Omadacycline injection and oral products. FDA identified breakpoints. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm622612.htm. Accessed November 13, 2018."},{"key":"bibr28-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"bibr29-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01393-16"},{"key":"bibr30-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1213465"},{"key":"bibr31-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.814"},{"key":"bibr32-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-17"},{"key":"bibr33-1060028018818094","volume-title":"Poster presented at: 26th European Congress of Clinical Microbiology and Infectious Diseases","author":"Tanaka SK"},{"key":"bibr34-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"bibr35-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"bibr36-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-17"},{"key":"bibr37-1060028018818094","volume-title":"Paper presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Ting L"},{"key":"bibr38-1060028018818094","unstructured":"O\u2019Riordan WA, Green S, Overcash JS, et al. A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study). https:\/\/paratekpharma.com\/media\/1410\/eccmid-oasis-oral-final-22apr2017-vff.pdf. Accessed June 27, 2018."},{"key":"bibr39-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Omadacycline in acute skin skin structure infections study (OASIS-2). https:\/\/paratekpharma.com\/media\/1462\/final-top-line-16301-absssi-17-july-2017-v1-investor-presentation.pdf. Published July 17, 2017. Accessed June 27, 2018."},{"key":"bibr40-1060028018818094","unstructured":"Paratek Pharmaceuticals Inc. Omadacycline: Antimicrobial Drugs Advisory Committee Meeting, August 2018. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM619389.pdf. Accessed November 14, 2018."},{"key":"bibr41-1060028018818094","volume-title":"Poster presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases","author":"O\u2019Riordan WA"},{"key":"bibr42-1060028018818094","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. http:\/\/cid.oxfordjournals.org\/content\/early\/2014\/06\/14\/cid.ciu296.full.pdf+html. Published July 15, 2014. Accessed November 6, 2018."},{"key":"bibr43-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1413"},{"key":"bibr44-1060028018818094","unstructured":"Ramirez J, Garrity-Ryan L, Eckburg PB, et al. Early clinical response of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by PORT risk class: results from the OPTIC study. https:\/\/paratekpharma.com\/media\/1571\/presentation-ats-2018-a4458-ramirez-optic-ecr-by-port-17.pdf. Published May 24, 2018. Accessed July 13, 2018."},{"key":"bibr45-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"bibr46-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00320-16"},{"key":"bibr47-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"bibr48-1060028018818094","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"bibr49-1060028018818094","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix833"},{"key":"bibr50-1060028018818094","unstructured":"Paratek Pharmaceuticals, Inc. Paratek presents pre-clinical data on the effects of omadacycline on\n                      Clostridium difficile\n                      . http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2155826. Published April 11, 2016. Accessed November 14, 2018."},{"key":"bibr51-1060028018818094","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics4020216"},{"key":"bibr52-1060028018818094","unstructured":"Tetraphase Pharmaceuticals, Inc. Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (CUTI). Globe Newswire. https:\/\/ir.tphase.com\/news-releases\/news-release-details\/tetraphase-announces-top-line-results-ignite3-phase-3-clinical. Published February 13, 2018. Accessed November 13, 2018."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018818094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028018818094","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018818094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:47Z","timestamp":1777374887000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018818094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1177\/1060028018818094"],"URL":"https:\/\/doi.org\/10.1177\/1060028018818094","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]}}}